Exact Mass: 550.2625282
Exact Mass Matches: 550.2625282
Found 135 metabolites which its exact mass value is equals to given mass value 550.2625282
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Manumycin A
C31H38N2O7 (550.2678877999999)
A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. Manumycin A is a polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. It has a role as an EC 1.8.1.9 (thioredoxin reductase) inhibitor, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor, an antineoplastic agent, an apoptosis inducer, an antimicrobial agent, a bacterial metabolite, an antiatherosclerotic agent and a marine metabolite. It is a polyketide, an enamide, an epoxide, an organic heterobicyclic compound, a secondary carboxamide and a tertiary alcohol. Manumycin A is a natural product found in Streptomyces, Streptomyces griseoaurantiacus, and Streptomyces parvulus D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors
Manumycin A
C31H38N2O7 (550.2678877999999)
PA(2:0/PGF2alpha)
C25H43O11P (550.2542857999999)
PA(2:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGF2alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF2alpha/2:0)
C25H43O11P (550.2542857999999)
PA(PGF2alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/2:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/PGE1)
C25H43O11P (550.2542857999999)
PA(2:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGE1), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGE1/2:0)
C25H43O11P (550.2542857999999)
PA(PGE1/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/2:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/PGD1)
C25H43O11P (550.2542857999999)
PA(2:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGD1), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGD1/2:0)
C25H43O11P (550.2542857999999)
PA(PGD1/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/2:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(3S,5R,6S,7E,9S)-megastigman-7-ene-5,6-epoxy-3,9-diol
1-O-cinnamoyl-17-defurano-17-oxosalannicacid methyl ester|17-defurano-17-oxoohchinin
3-O-angeloyl-17-(benzoyloxy)ingenol|ingenol-3-angelate-17-benzoate
Ala Phe Gln Trp
C28H34N6O6 (550.2539704000001)
Ala Phe Trp Gln
C28H34N6O6 (550.2539704000001)
Ala Gln Phe Trp
C28H34N6O6 (550.2539704000001)
Ala Gln Trp Phe
C28H34N6O6 (550.2539704000001)
Ala Trp Phe Gln
C28H34N6O6 (550.2539704000001)
Ala Trp Gln Phe
C28H34N6O6 (550.2539704000001)
Phe Ala Gln Trp
C28H34N6O6 (550.2539704000001)
Phe Ala Trp Gln
C28H34N6O6 (550.2539704000001)
Phe Phe His Thr
C28H34N6O6 (550.2539704000001)
Phe Phe Thr His
C28H34N6O6 (550.2539704000001)
Phe His Phe Thr
C28H34N6O6 (550.2539704000001)
Phe His Thr Phe
C28H34N6O6 (550.2539704000001)
Phe Gln Ala Trp
C28H34N6O6 (550.2539704000001)
Phe Gln Trp Ala
C28H34N6O6 (550.2539704000001)
Phe Thr Phe His
C28H34N6O6 (550.2539704000001)
Phe Thr His Phe
C28H34N6O6 (550.2539704000001)
Phe Trp Ala Gln
C28H34N6O6 (550.2539704000001)
Phe Trp Gln Ala
C28H34N6O6 (550.2539704000001)
His Phe Phe Thr
C28H34N6O6 (550.2539704000001)
His Phe Thr Phe
C28H34N6O6 (550.2539704000001)
His Thr Phe Phe
C28H34N6O6 (550.2539704000001)
Lys Met Ser Trp
C25H38N6O6S (550.2573408000001)
Lys Met Trp Ser
C25H38N6O6S (550.2573408000001)
Lys Ser Met Trp
C25H38N6O6S (550.2573408000001)
Lys Ser Trp Met
C25H38N6O6S (550.2573408000001)
Lys Trp Met Ser
C25H38N6O6S (550.2573408000001)
Lys Trp Ser Met
C25H38N6O6S (550.2573408000001)
Met Lys Ser Trp
C25H38N6O6S (550.2573408000001)
Met Lys Trp Ser
C25H38N6O6S (550.2573408000001)
Met Ser Lys Trp
C25H38N6O6S (550.2573408000001)
Met Ser Trp Lys
C25H38N6O6S (550.2573408000001)
Met Trp Lys Ser
C25H38N6O6S (550.2573408000001)
Met Trp Ser Lys
C25H38N6O6S (550.2573408000001)
Gln Ala Phe Trp
C28H34N6O6 (550.2539704000001)
Gln Ala Trp Phe
C28H34N6O6 (550.2539704000001)
Gln Phe Ala Trp
C28H34N6O6 (550.2539704000001)
Gln Phe Trp Ala
C28H34N6O6 (550.2539704000001)
Gln Trp Ala Phe
C28H34N6O6 (550.2539704000001)
Gln Trp Phe Ala
C28H34N6O6 (550.2539704000001)
Ser Lys Met Trp
C25H38N6O6S (550.2573408000001)
Ser Lys Trp Met
C25H38N6O6S (550.2573408000001)
Ser Met Lys Trp
C25H38N6O6S (550.2573408000001)
Ser Met Trp Lys
C25H38N6O6S (550.2573408000001)
Ser Trp Lys Met
C25H38N6O6S (550.2573408000001)
Ser Trp Met Lys
C25H38N6O6S (550.2573408000001)
Thr Phe Phe His
C28H34N6O6 (550.2539704000001)
Thr Phe His Phe
C28H34N6O6 (550.2539704000001)
Thr His Phe Phe
C28H34N6O6 (550.2539704000001)
Trp Ala Phe Gln
C28H34N6O6 (550.2539704000001)
Trp Ala Gln Phe
C28H34N6O6 (550.2539704000001)
Trp Phe Ala Gln
C28H34N6O6 (550.2539704000001)
Trp Phe Gln Ala
C28H34N6O6 (550.2539704000001)
Trp Lys Met Ser
C25H38N6O6S (550.2573408000001)
Trp Lys Ser Met
C25H38N6O6S (550.2573408000001)
Trp Met Lys Ser
C25H38N6O6S (550.2573408000001)
Trp Met Ser Lys
C25H38N6O6S (550.2573408000001)
Trp Gln Ala Phe
C28H34N6O6 (550.2539704000001)
Trp Gln Phe Ala
C28H34N6O6 (550.2539704000001)
Trp Ser Lys Met
C25H38N6O6S (550.2573408000001)
Trp Ser Met Lys
C25H38N6O6S (550.2573408000001)
benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid
Manumycin A
C31H38N2O7 (550.2678877999999)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors
(R)-2,4,6-Trimethyl-deca-2,4-dienoic acid {(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-6-(2-hydroxy-5-oxo-cyclopent-1-enylcarbamoyl)-hexa-1,3,5-trienyl]-2-oxo-7-oxa-bicyclo[4.1.0]hept-3-en-3-yl}-amide
C31H38N2O7 (550.2678877999999)
(2E,4E,6R)-N-[(5S,6R)-5-[(1E,3E,5E)-7-[(2,5-dioxocyclopentyl)amino]-7-oxohepta-1,3,5-trienyl]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide
C31H38N2O7 (550.2678877999999)
[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
(9ar,11as)-1-{2-hydroxy-1-[5-(methoxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl}-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthrene-7-sulfonic acid
(9r,13s,16s,17r,18s)-16-[(1r)-1-hydroxy-1-[(2s)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate
(2e,4e,6r)-n-[(1s,5s,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid
C31H38N2O7 (550.2678877999999)
(1r,2s,5r,6r,13s,14r,16s)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadeca-9,11-dien-14-yl (2z)-2-methylbut-2-enoate
10'-hydroxy-1',6,6',9,10'-pentamethyl-2,5',7-trioxo-4,5,9a,9b-tetrahydro-3ah-4'-oxaspiro[azuleno[4,5-b]furan-3,14'-tetracyclo[10.2.1.0²,¹¹.0³,⁷]pentadecan]-2'(11')-en-8'-yl acetate
5,5-dimethyl-4-(3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)cyclohex-2-en-1-one
[(1s,4s,5s,6r,9s,10r,11r,12r,14r)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,14-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate
(2s)-2-methyl-1-[9,12,14-trihydroxy-13-(2-hydroxy-3-methylbut-3-en-1-yl)-5,5-dimethyl-8-[(2s)-2-methylbutanoyl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2(7),3,8,11(16),12,14-heptaen-15-yl]butan-1-one
(4s,7s,18s,21s)-3,9,17,23-tetrahydroxy-4,5,7,18,19,21-hexamethyl-2,5,8,16,19,22-hexaazatricyclo[22.4.0.0¹⁰,¹⁵]octacosa-1(28),2,8,10,12,14,16,22,24,26-decaene-6,20-dione
C28H34N6O6 (550.2539704000001)
(4r)-3-(hydroxymethyl)-5,5-dimethyl-4-[(3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one
[(1s,4s,5r,6r,9s,10r,11r,12r,14r)-4,5,6-trihydroxy-3,11,14-trimethyl-7-({[(2z)-2-methylbut-2-enoyl]oxy}methyl)-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate
(1s,4r,11r,14s,17s,20r)-4-[(2s)-butan-2-yl]-14-[(1r)-1-hydroxyethyl]-17-isopropyl-11,20-dimethyl-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-2,5(22),7,9,12,15,18(21)-heptaene-2,9,12,15-tetrol
C25H38N6O6S (550.2573408000001)
4-hydroxy-3,5,5-trimethyl-4-(3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl)cyclohex-2-en-1-one
2-(hydroxymethyl)-6-{[1,5,5-trimethyl-6-(3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-1-en-1-yl)-7-oxabicyclo[4.1.0]heptan-3-yl]oxy}oxane-3,4,5-triol
3,9,17,23-tetrahydroxy-4,5,7,18,19,21-hexamethyl-2,5,8,16,19,22-hexaazatricyclo[22.4.0.0¹⁰,¹⁵]octacosa-1(28),2,8,10,12,14,16,22,24,26-decaene-6,20-dione
C28H34N6O6 (550.2539704000001)
(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(1r,3s,6s)-1,5,5-trimethyl-6-[(1e,3s)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-1-en-1-yl]-7-oxabicyclo[4.1.0]heptan-3-yl]oxy}oxane-3,4,5-triol
(4,5,6-trihydroxy-3,11,14-trimethyl-7-{[(2-methylbut-2-enoyl)oxy]methyl}-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl)methyl benzoate
16-[1-hydroxy-1-(5-methyl-6-oxo-2,3-dihydropyran-2-yl)ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate
(1's,3r,3's,3as,6's,7'r,8's,9as,9bs,10'r,12's)-10'-hydroxy-1',6,6',9,10'-pentamethyl-2,5',7-trioxo-4,5,9a,9b-tetrahydro-3ah-4'-oxaspiro[azuleno[4,5-b]furan-3,14'-tetracyclo[10.2.1.0²,¹¹.0³,⁷]pentadecan]-2'(11')-en-8'-yl acetate
14-(1-hydroxyethyl)-17-isopropyl-11,20-dimethyl-4-(sec-butyl)-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-2,5(22),7,9,12,15,18(21)-heptaene-2,9,12,15-tetrol
C25H38N6O6S (550.2573408000001)
3-(hydroxymethyl)-5,5-dimethyl-4-(3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl)cyclohex-2-en-1-one
(4s)-4-hydroxy-3,5,5-trimethyl-4-[(3s)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one
(4s)-5,5-dimethyl-4-[(3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)cyclohex-2-en-1-one
(2e,4e,6r)-n-[(1s,5r,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid
C31H38N2O7 (550.2678877999999)
n-[(1r,5s,6r)-5-hydroxy-5-{6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl}-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid
C31H38N2O7 (550.2678877999999)